nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

17.08.2023 | Research

Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study

verfasst von: Yangxun Pan, Ze Yuan, Jiongliang Wang, Siegmund Ngai, Zhiwen Hu, Liyang Sun, Zhenyun Yang, Dandan Hu, Minshan Chen, Zhongguo Zhou, Yaojun Zhang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 16/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Recently, the conversion therapies of FOLFOX-HAIC for patients with unresectable hepatocellular carcinoma (uHCC) have dramatically increased the tumor responses and conversion rate; thus, the prognosis of uHCC patients was expected to be prolonged. However, the postoperative recurrence of uHCC patients who successfully underwent conversion therapies stayed high. The present study evaluated the efficacy and safety of postoperatively adjuvant therapy in treating uHCC patients who received FOLFOX-HAIC-based conversion therapy.

Methods

In this real-world retrospective study, uHCC patients who received FOLFOX-HAIC-based conversion therapy were included. The recurrence-free survival (RFS), as primary outcomes, was compared between patients who received adjuvant therapy (AT group) or non-adjuvant therapy (nAT group) using survival analysis and Cox regression. Imbalances in baseline clinical features between the two groups were adjusted through propensity score matching (PSM) and inverse probability of treatment weighting (IPTW).

Results

Between January 2016 and December 2022, 204 uHCC patients who received FOLFOX-HAIC-based conversion therapy were included and assigned into AT group (n = 47) and nAT group (n = 157), respectively. The median RFS was significantly longer in the AT group than the nAT group before adjustment [19.2 vs. 10.8 months; hazard ratio (HR), 0.584; 95% CI, 0.383–0.892; P = 0.028], after PSM and after IPTW. Subsequent subgroup analyses revealed the RFS of adjuvant therapy was best in uHCC patients with younger than 60 years, macrovascular invasion, and positive hepatitis B surface antigen.

Conclusion

Postoperatively, adjuvant therapy was associated with improved survival outcomes compared with non-adjuvant therapy after FOLFOX-HAIC-based conversion therapy among uHCC patients, especially for patients with macrovascular invasion and positive hepatitis B surface antigen.

Nur mit Berechtigung zugänglich

Anwanwan D, Singh SK, Singh S et al (2020) Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer 1873:188314PubMedCrossRef

Aubert CE, Ha J-K, Kim HM et al (2021) Clinical outcomes of modifying hypertension treatment intensity in older adults treated to low blood pressure. J Am Geriatr Soc 69:2831–2841PubMedPubMedCentralCrossRef

Benson AB, D’Angelica MI, Abbott DE et al (2021) Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 19:541–565CrossRef

Bruix J, Takayama T, Mazzaferro V et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16:1344–1354PubMedCrossRef

Chen S, Wu Z, Shi F et al (2022) Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol 148:2115–2125PubMedCrossRef

Chong CCN, Wong GLH, Wong VWS et al (2015) Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther 41:199–208PubMedCrossRef

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502PubMedPubMedCentralCrossRef

European Association for the Study of the Liver (2018) Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef

Finn RS, Ikeda M, Zhu AX et al (2020) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38:2960–2970PubMedPubMedCentralCrossRef

Finn RS, Ikeda M, Zhu AX et al (2020a) Phase Ib study of Lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38:2960–2970PubMedPubMedCentralCrossRef

Finn RS, Qin S, Ikeda M et al (2020b) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905PubMedCrossRef

He M, Li Q, Shi M (2019) Potential areas of interest in a trial of sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for hepatocellular carcinoma-in reply. JAMA Oncol 5:1806–1807PubMedCrossRef

He M-K, Liang R-B, Zhao Y et al (2021) Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol 13:17588359211002720PubMedPubMedCentralCrossRef

Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380PubMedCrossRef

Hu L, Zheng Y, Lin J et al (2023) Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis. World J Surg Oncol 21:121PubMedPubMedCentralCrossRef

Huang G, Li P-P, Lau WY et al (2018) Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg 268:943–954PubMedCrossRef

Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173PubMedCrossRef

Kudo M, Morimoto M, Moriguchi M et al (2020) A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci 111:3759–3769PubMedPubMedCentralCrossRef

Lai Z, Huang Y, Wen D et al (2022) One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. BMC Med 20(1):1–2CrossRef

Li Q-J, He M-K, Chen H-W et al (2022) Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol 40:150–160PubMedCrossRef

Li S-H, Mei J, Cheng Y et al (2023) Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III. Randomized Study JCO 41:1898–1908

Llovet JM, Zucman-Rossi J, Pikarsky E et al (2016) Hepatocellular carcinoma. Nat Rev Dis Primers 2:16018PubMedCrossRef

Llovet JM, Kelley RK, Villanueva A et al (2021a) Hepatocellular Carcinoma. Nat Rev Dis Primers 7:6PubMedCrossRef

Llovet JM, De Baere T, Kulik L et al (2021b) Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18:293–313PubMedCrossRef

Llovet JM, Castet F, Heikenwalder M et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19:151–172PubMedCrossRef

Park J-W, Chen M, Colombo M et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35:2155–2166PubMedPubMedCentralCrossRef

Ramos MFKP, Pereira MA, Charruf AZ et al (2019) Conversion therapy for gastric cancer: expanding the treatment possibilities. Arq Bras Cir Dig 32:e1435PubMedPubMedCentralCrossRef

Rubin DB, Thomas N (1996) Matching using estimated propensity scores: relating theory to practice. Biometrics 52:249PubMedCrossRef

Rumgay H, Arnold M, Ferlay J et al (2022) Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 77:1598–1606PubMedPubMedCentralCrossRef

Sangro B, Gomez-Martin C, de la Mata M et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59:81–88PubMedCrossRef

Scorsetti M, Comito T, Cozzi L et al (2015) The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 141:1301–1309PubMedCrossRef

Shi J, Lai ECH, Li N et al (2010) Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 17:2073–2080PubMedCrossRef

Sun H-C, Zhou J, Wang Z et al (2022) Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr 11:227–252PubMedPubMedCentralCrossRef

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249PubMedCrossRef

Tang ZY, Uy YQ, Zhou XD et al (1995) Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients. World J Surg 19:784–789PubMedCrossRef

Vogel A, Cervantes A, Chau I et al (2018) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv238–iv255PubMedCrossRef

Wei X, Jiang Y, Zhang X et al (2019) Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol 37:2141–2151PubMedPubMedCentralCrossRef

Zhang W, Zhao G, Wei K et al (2014) Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. BST 8:333–338CrossRef

Zhang B, Xu D, Wang R et al (2015) Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. Int J Surg 15:1–5PubMedCrossRef

Zhang Y, Huang G, Wang Y et al (2016) Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? Ten years of experience. Oncologist 21:1442–1449PubMedPubMedCentralCrossRef

Zhang X-P, Chai Z-T, Gao Y-Z et al (2019) Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB 21:1687–1696PubMedCrossRef

Zhong J, Ke Y, Gong W et al (2014) Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg 260:329–340PubMedCrossRef

Zhou J, Sun H-C, Wang Z et al (2018) Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer. 7:235–260PubMedPubMedCentralCrossRef

Zhou M, Wang H, Zeng X et al (2019a) Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 394:1145–1158PubMedPubMedCentralCrossRef

Zhou J, Sun H, Wang Z et al (2020) Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer 9:682–720PubMedPubMedCentralCrossRef

Zhu X-D, Huang C, Shen Y-H et al (2021) Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer 10:320–329PubMedPubMedCentralCrossRef

Titel: Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study
verfasst von: Yangxun Pan
Ze Yuan
Jiongliang Wang
Siegmund Ngai
Zhiwen Hu
Liyang Sun
Zhenyun Yang
Dandan Hu
Minshan Chen
Zhongguo Zhou
Yaojun Zhang
Publikationsdatum: 17.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 16/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05243-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study